Japanese Patient Studies The Japanese patient studies revealed similar patterns, with tirzepatide outperforming traditional GLP-1 receptor agonists in both weight management and glycemic control
It is not for human or veterinary consumption and must not be used as a drug, food additive, cosmetic, or household item
\Improved Tolerability: Smoother PK profile may reduce GI-related adverse events
Obesity also increases the risk of hypertension and dyslipidemia, both of which damage vascular health and contribute to ED
GLP-1 (glucagon-like peptide 1) slows the rate at which food leaves your stomach (gastric emptying), reduces appetite by acting on hunger centers in the brain, and stimulates glucose-dependent insulin secretion
Clinicians should carefully consider use in patients with significant motility disorders, inflammatory bowel disease with strictures, or severe chronic constipation